Cangene gets OK for hepatitis B therapy

Canada's Cangene has received FDA approval for HepaGam B, a treatment for hepatitis B. Cangene says it expects to start marketing the drug in the next few months. Some 2 billion people have been infected with the hepatitis B virus. "This is Cangene's fourth approved drug and the third drug to receive FDA approval--a significant accomplishment for a biopharmaceutical company," said Dr. John Langstaff, Cangene's president and CEO.

- read this release for more information